AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Harvard Bioscience Names John Duke as New President and CEO, Replacing Jim Green in July 2025.
ByAinvest
Saturday, Jul 19, 2025 8:35 am ET1min read
Harvard Bioscience has announced CEO John Duke to replace Jim Green, who will retire in July 2025. Duke is currently the CEO of Plastic Molding Technology and serves on Harvard Bioscience's Board of Directors. The company reported a Q1 2025 revenue of $21.8 million, down from $24.5 million in Q1 2024, and a net loss of $49.7 million due to a $48 million goodwill impairment charge. Despite this, Harvard Bioscience expects new products like the SoHo family of implanted telemetry devices and the VivaMARS system to drive future growth.
Harvard Bioscience, Inc. (Nasdaq: HBIO) has announced that John Duke will become the new President and CEO of the company, effective July 28, 2025, following the retirement of Jim Green. This transition comes as Green prepares to step down after over eight years in leadership roles [1].John Duke, who currently serves on the Board of Directors, will replace Jim Green. Duke has a strong background in the life sciences sector, having previously led Plastic Molding Technology and held executive roles at Corning Incorporated. His tenure at Plastic Molding Technology saw approximately 20% annual revenue growth [1].
The company also announced the appointment of Rob Gagnon and Seth Benson to the Board of Directors, effective July 16, 2025. Rob Gagnon has extensive experience in global finance operations within the life sciences industry, while Seth Benson brings expertise in finance, technology, and operations, including significant time spent in life science tools [1].
Despite the recent Q1 2025 financial results, which showed a revenue of $21.8 million, down from $24.5 million in Q1 2024, and a net loss of $49.7 million due to a $48 million goodwill impairment charge, Harvard Bioscience expects new products like the SoHo family of implanted telemetry devices and the VivaMARS system to drive future growth [2].
The company anticipates a revenue of $20.4 million for Q2 2025 and has reaffirmed its gross margin guidance of 55% to 57% for the same period, with financial results to be reported on August 11, 2025 [1].
References:
[1] https://www.nasdaq.com/articles/harvard-bioscience-announces-john-duke-new-president-ceo-following-jim-greens-retirement
[2] https://www.harvardbioscience.com
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet